Is Unity Software a Buy Now?
Unity Software (NYSE:U) is the company behind the popular Unity…
Sell
34
IOBT Quote, Financials, Valuation and Earnings
Last price:
$0.98
Seasonality move
:
-21.02%
Day range:
$0.97 - $1.03
52-week range:
$0.66 - $1.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.37x
Volume:
86.1K
Avg. volume:
108.7K
1-year change:
-30%
Market cap:
$64.6M
Revenue:
--
EPS (TTM):
-$1.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IOBT
IO Biotech
|
-- | -$0.23 | -- | -23.33% | $9.50 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.28 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -8.25% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IOBT
IO Biotech
|
$0.98 | $9.50 | $64.6M | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals
|
$1.67 | $5.00 | $52.1M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.59 | $0.85 | $3.4M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.41 | -- | $22.1M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.20 | $1.00 | $4.3M | -- | $0.00 | 0% | 1.92x |
|
TOVX
Theriva Biologics
|
$0.56 | $7.00 | $1.6M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IOBT
IO Biotech
|
-- | -3.128 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.541 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | 2.080 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.254 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -2.512 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IOBT
IO Biotech
|
-- | -$26.5M | -- | -- | -- | -$20.8M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
NNVC
Nanoviricides
|
-- | -$2.1M | -- | -- | -- | -$2.2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
IO Biotech vs. Competitors
-
Which has Higher Returns IOBT or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to IO Biotech's net margin of -11511.11%. IO Biotech's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.36 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About IOBT or ATNM?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 199.4%. Given that IO Biotech has higher upside potential than Actinium Pharmaceuticals, analysts believe IO Biotech is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is IOBT or ATNM More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.
-
Which is a Better Dividend Stock IOBT or ATNM?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or ATNM?
IO Biotech quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. IO Biotech's net income of -$24M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, IO Biotech's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$24M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns IOBT or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to IO Biotech's net margin of -49.65%. IO Biotech's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.36 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About IOBT or NBY?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.07%. Given that IO Biotech has higher upside potential than NovaBay Pharmaceuticals, analysts believe IO Biotech is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is IOBT or NBY More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock IOBT or NBY?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or NBY?
IO Biotech quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IO Biotech's net income of -$24M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, IO Biotech's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$24M NBYNovaBay Pharmaceuticals0.16x -- $2.4M -$1.2M
-
Which has Higher Returns IOBT or NNVC?
Nanoviricides has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.36 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About IOBT or NNVC?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 360.99%. Given that IO Biotech has higher upside potential than Nanoviricides, analysts believe IO Biotech is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 NNVCNanoviricides0 0 0 -
Is IOBT or NNVC More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.
-
Which is a Better Dividend Stock IOBT or NNVC?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or NNVC?
IO Biotech quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. IO Biotech's net income of -$24M is lower than Nanoviricides's net income of -$2M. Notably, IO Biotech's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$24M NNVCNanoviricides-- -- -- -$2M
-
Which has Higher Returns IOBT or OGEN?
Oragenics has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.36 -- OGENOragenics-- -$0.12 -- -
What do Analysts Say About IOBT or OGEN?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 400%. Given that IO Biotech has higher upside potential than Oragenics, analysts believe IO Biotech is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 OGENOragenics0 1 0 -
Is IOBT or OGEN More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.
-
Which is a Better Dividend Stock IOBT or OGEN?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or OGEN?
IO Biotech quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. IO Biotech's net income of -$24M is lower than Oragenics's net income of -$2.2M. Notably, IO Biotech's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 1.92x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$24M OGENOragenics1.92x -- -- -$2.2M
-
Which has Higher Returns IOBT or TOVX?
Theriva Biologics has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IOBTIO Biotech-- -$0.36 -- TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About IOBT or TOVX?
IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1152.68%. Given that Theriva Biologics has higher upside potential than IO Biotech, analysts believe Theriva Biologics is more attractive than IO Biotech.
Company Buy Ratings Hold Ratings Sell Ratings IOBTIO Biotech2 0 0 TOVXTheriva Biologics1 1 0 -
Is IOBT or TOVX More Risky?
IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.
-
Which is a Better Dividend Stock IOBT or TOVX?
IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOBT or TOVX?
IO Biotech quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. IO Biotech's net income of -$24M is lower than Theriva Biologics's net income of -$4.4M. Notably, IO Biotech's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOBTIO Biotech-- -- -- -$24M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock 5X?
Uber (NYSE:UBER) has generated extremely strong returns for its investors…
How High Will Bloom Energy Stock Go?
Bloom Energy (NYSE:BE) has seen its shares surge by more…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
81
SMLR alert for May 17
Semler Scientific [SMLR] is up 28.56% over the past day.
Sell
25
GLOB alert for May 17
Globant SA [GLOB] is down 23.54% over the past day.
Buy
94
HIMS alert for May 17
Hims & Hers Health [HIMS] is up 10.38% over the past day.
